TheraRadar
Clinical-Stage Companies / CStone

CStone

Pre-Approval PRO BETA
26
Total Trials
6
Phase 3
7
Phase 2
5
Recruiting
202
Score

Pipeline by Phase

Phase 3
6
Phase 2
7
Phase 1
17

Therapeutic Focus

Advanced Solid Tumor Advanced Solid Tumors Hepatocellular Carcinoma Solid Tumor, Adult Advanced Cancer

Clinical Trials (26)

NCT05700448 Phase 3 NOT YET RECRUITING

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Started: 6/1/2026

NCT04194775 Phase 3 ACTIVE NOT RECRUITING

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

Started: 12/13/2019

NCT03789604 Phase 3 ACTIVE NOT RECRUITING

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

Started: 12/13/2018

NCT03802591 Phase 3 COMPLETED

A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

Started: 3/28/2019

NCT04187352 Phase 3 COMPLETED

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Started: 12/19/2019

NCT03728556 Phase 3 COMPLETED

A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

Started: 10/26/2018

NCT05297890 Phase 2 ACTIVE NOT RECRUITING

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Started: 5/27/2022

NCT03595657 Phase 2 COMPLETED

A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)

Started: 6/12/2018

NCT03505996 Phase 2 COMPLETED

A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Started: 5/22/2018

NCT06741644 Phase 1 RECRUITING

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Started: 2/24/2025

NCT05279300 Phase 1 RECRUITING

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Started: 3/28/2022

NCT03516123 Phase 1 COMPLETED

A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors

Started: 6/14/2018

NCT03523819 Phase 1 COMPLETED

A Study of CS1002 in Subjects with Advanced Solid Tumors

Started: 4/26/2018

NCT03744403 Phase 1 COMPLETED

A Study of CS1001 in Subjects with Advanced Solid Tumors

Started: 12/4/2018

NCT04421352 Phase 1 COMPLETED

Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

Started: 1/12/2021

NCT04254939 Phase 1 COMPLETED

A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Started: 8/15/2019

NCT04176393 Phase 1 COMPLETED

A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

Started: 11/12/2019

NCT04194801 Phase 1 COMPLETED

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Started: 12/16/2019

NCT03809767 Phase 1 COMPLETED

A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Started: 10/29/2018

NCT03312842 Phase 1 COMPLETED

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

Started: 10/19/2017

NCT04200404 Phase 1 COMPLETED

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Started: 12/13/2019

NCT04233060 Phase 1 COMPLETED

A Study of CS3005 in Advanced Solid Tumors

Started: 1/10/2020

NCT03475251 Phase 1 COMPLETED

A Study of CS1003 in Subjects With Advanced Solid Tumors

Started: 5/9/2018

NCT04162301 Phase 1 TERMINATED

A Study of CS3002 in Subjects With Advanced Solid Tumors

Started: 12/30/2019

NCT04338724 Phase 1 COMPLETED

A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors

Started: 12/27/2019

NCT03736850 Phase 1 COMPLETED

Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Started: 10/19/2018

Drug Candidates

CS2009 Pemetrexed Carboplatin Paclitaxel Etoposide Nab-paclitaxel Oxaliplatin Capecitabine Docetaxel Leucovorin
Activity Status: Active
Last Trial Started: 6/1/2026
Last Trial Ended: 12/22/2023
Trials (12 months): 1
Completed Trials: 19
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.